Page not found!

Sorry the page you are looking for no longer exists in this location.

We apologise for the inconvenience.

Please use the navigation on this page to locate other resources on this site.


Latest Headlines


Bayer Files Lawsuit Against Teva

Lawsuit concerns Teva's application for approval to market Levitra for the treatment of erectile dysfunction

Sanofi-aventis Receives FDA Approval For Multaq

Multaq to treat patients with atrial fibrillation or atrial flutter

Dow To Streamline Manufacturing Footprint

Calls for shutdown of a number of manufacturing assets, including ethylene and ethylene-derivative assets

Myriad Genetics Spins Off Research, Pharmaceutical Business

Myriad Genetics to claim approximately $400 million in tax deductions

GSK Extends Product Portfolio In Middle East, North Africa

Business comprises a portfolio of 13 branded pharmaceuticals

Biogen Idec, Acorda Sign Collaboration Agreement For Fampridine-SR

Acorda to continue developing and commercializing Fampridine-SR in the US

Graceway Signs Acquisition, License Agreement With Pfizer

Graceway to acquire worldwide commercial rights for three investigational dermatological molecules from Pfizer

Morphotek Signs Collaboration Agreement With Synageva

To develop therapeutic monoclonal antibodies for treatment of various forms of cancer and infectious disease

Sepracor Provides Update On Clinical Trials For SEP-225289, Lunesta

SEP-225289 did not meet the primary efficacy endpoint, but Lunesta has been proven to be safe and well tolerated

Shire Provides Results For Phase 3b Vyvanse Study

Vyvanse improved the ability to focus and organize, as well as hyperactivity and impulsivity

Schering-Plough Presents Phase II and III Data For Corifollitropin Alfa

Corifollitropin Alfa provides treatment in Controlled Ovarian Stimulation for development of multiple follicles in women

More Articles...

Comments & Opinion

Pandemic flu: gaps in preparedness remain

The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.

Neurology conference reports little progress in neurodegenerative disorders

The neurodegenerative disease market saw few major announcements at this year's recent American Academy of Neurology conference. While the Alzheimer's disease field must wait until next year before efficacy data from late-stage pipeline drugs are released, Parkinson's disease announcements were restricted to post-marketing studies designed to reposition treatments or protect vulnerable franchises.

Antiviral sales boosted as UAE prepares for influenza A (H1N1)

The recent outbreak of influenza A (H1N1) infection, previously referred to as swine flu, has thrown the spotlight on governments around the world and their ability to manage a pandemic. In the UAE, customers are currently finding it difficult to source antivirals but, with Dubai seen as a hub for international travel, the government has stockpiles ready for distribution should an outbreak occur.

Genentech/Roche: Avastin adds fifth indication to label

Following positive results from two Phase II trials, Genentech/Roche's Avastin has obtained accelerated FDA approval for glioblastoma patients who have progressed after previous treatment. While the commercial potential in this indication is small, it creates an opportunity for Avastin to become an established treatment in this type of brain cancer.

New oral multiple sclerosis drugs edge closer to market

With little market-shifting information announced across most neurological conditions at this year's AAN conference, it was left to the multiple sclerosis field to take center stage. Notably, Merck KGaA and Novartis presented positive Phase III data for their front running pipeline agents oral cladribine and FTY720 respectively. However, safety issues remain a concern for both products.

More Comments...



Newsletter Subscriptions